AEGiS-07CROI: Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI-substitution.

7th Conference on Retroviruses and Opportunistic Infections

San Francisco, CA - January 30 -February 4, 2000

IDENTIFICATION OF FAT REDISTRIBUTION/METABOLIC ANOMALIES IN A COHORT TREATED BY 2 NRTIs + 1 PI, AND ABSENCE OF SIGNIFICANT MODIFICATION FOLLOWING PI-SUBSTITUTION.

Conf Retroviruses Opportunistic Infect 2000 Jan 30-Feb 2; 7:84 (abstract no. 46)

S. Gharakhanian, Y. Salhi, N. Adda, C. Vigouroux, J. Capeau, And W. Rozenbaum
Rothschild Hosp., Paris, France.

AIM: To identify clinical/laboratory features and risk factors of the HIV-associated lipodystrophy sydrom in a cohort treated by 2 NRTIs & 1 PI, providing a framework to allow an evaluation of the impact of antiretroviral modifications.

METHODS: Cross sectional study of pts treated by PI for > 3 months by a comprehensive examination including 14 clinical & anthropometric endpoints, lipid, glucose (75gr OGTT), insulin dosage. In a subset of these pts with HIV RNA < 500cp/ml and at least one clinical and laboratory anomaly, PI was substituted for efavirenz, with NRTI unchanged, and pts were followed-up prospectively for a year.

RESULTS: 624 pts (84% M, 16% F), aged 40 ± 9 yrs, AIDS in 31% were studied in an HIV referral center. Frequency of clinical anomalies was high (85%), with differences between the sexes Tri-/bicipital skinfold show the most consistent change albeit subject to variability. 3 clinical subtypes were identified: atrophic pts (20%), pts with increased adiposity (22%), mixed/heterogenous types (58%). 34% had glucose intolerance/diabetes. 42% had hyperinsulinemia, Cholesterol was NCEP high/very high in 36% and triglycerides in 14% of pts. Duration of therapy is a notable risk factor. Thirty-three pts from this cohort treated by PI for a median of 24 months [5-35] mainly by indinavir (84%), associated with d4T/3TC in 81% of cases underwent substitution of PI by efavirenz. No significant difference was observed at month ten for weight, fat redistribution patterns, lipid & glucose/insulin abnormalities. 4 patients withdrew for adverse events of laboratory anomalies.

CONCLUSION: Fat redistribution is a chronic condition defined by clinical & laboratory anomalies. PI-substitution with efavirenz does not seem to lead to significant improvement of clinical or biological anomalies.

Keywords: AEGIS, HIV Protease Inhibitors, Lipodystrophy, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Stavudine, HIV Infections, Lamivudine, HIV-1, Acquired Immunodeficiency Syndrome, HIV, Insulin, Cross-Sectional Studies, HIV Wasting Syndrome, Diabetes Mellitus, Glucose Intolerance, Human, abnormalities, AIDS

2000-01-30
46

Copyright © 2000 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.